Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 9 |
| List of Tables | 9 | 1 |
| List of Figures | 10 | 1 |
| Introduction | 11 | 1 |
| Global Markets Direct Report Coverage | 11 | 1 |
| Pancreatic Ductal Adenocarcinoma Overview | 12 | 1 |
| Therapeutics Development | 13 | 2 |
| Pipeline Products for Pancreatic Ductal Adenocarcinoma Overview | 13 | 1 |
| Pipeline Products for Pancreatic Ductal Adenocarcinoma Comparative Analysis | 14 | 1 |
| Pancreatic Ductal Adenocarcinoma Therapeutics under Development by Companies | 15 | 2 |
| Pancreatic Ductal Adenocarcinoma Therapeutics under Investigation by Universities/Institutes | 17 | 1 |
| Pancreatic Ductal Adenocarcinoma Pipeline Products Glance | 18 | 3 |
| Late Stage Products | 18 | 1 |
| Clinical Stage Products | 19 | 1 |
| Early Stage Products | 20 | 1 |
| Pancreatic Ductal Adenocarcinoma Products under Development by Companies | 21 | 3 |
| Pancreatic Ductal Adenocarcinoma Products under Investigation by Universities/Institutes | 24 | 1 |
| Pancreatic Ductal Adenocarcinoma Companies Involved in Therapeutics Development | 25 | 33 |
| BerGenBio AS | 25 | 1 |
| BioNTech AG | 26 | 1 |
| Celgene Corporation | 27 | 1 |
| Clovis Oncology, Inc. | 28 | 1 |
| COARE Biotechnology, Inc. | 29 | 1 |
| Concordia International Corp | 30 | 1 |
| Eli Lilly and Company | 31 | 1 |
| FibroGen, Inc. | 32 | 1 |
| Gilead Sciences, Inc. | 33 | 1 |
| Halozyme Therapeutics, Inc. | 34 | 1 |
| Immodulon Therapeutics Ltd. | 35 | 1 |
| Immunomedics, Inc. | 36 | 1 |
| Incuron, LLC | 37 | 1 |
| Incyte Corporation | 38 | 1 |
| Inflection Biosciences Limited | 39 | 1 |
| Inovio Pharmaceuticals, Inc. | 40 | 1 |
| InvivoGen Therapeutics | 41 | 1 |
| MedImmune, LLC | 42 | 1 |
| Medisyn Technologies, Inc. | 43 | 1 |
| Merck &Co., Inc. | 44 | 1 |
| Nerviano Medical Sciences S.r.l. | 45 | 1 |
| Novartis AG | 46 | 1 |
| OncoMed Pharmaceuticals, Inc. | 47 | 1 |
| Ono Pharmaceutical Co., Ltd. | 48 | 1 |
| Oryx GmbH &Co. KG | 49 | 1 |
| Pfizer Inc. | 50 | 1 |
| Quest PharmaTech Inc. | 51 | 1 |
| Sillajen Biotherapeutics | 52 | 1 |
| Soricimed Biopharma Inc. | 53 | 1 |
| Sun BioPharma, Inc. | 54 | 1 |
| Swedish Orphan Biovitrum AB | 55 | 1 |
| Tara Immuno-Oncology Therapeutics LLC | 56 | 1 |
| Tokai Pharmaceuticals, Inc. | 57 | 1 |
| Pancreatic Ductal Adenocarcinoma Therapeutics Assessment | 58 | 13 |
| Assessment by Monotherapy Products | 58 | 1 |
| Assessment by Combination Products | 59 | 1 |
| Assessment by Target | 60 | 3 |
| Assessment by Mechanism of Action | 63 | 4 |
| Assessment by Route of Administration | 67 | 2 |
| Assessment by Molecule Type | 69 | 2 |
| Drug Profiles | 71 | 169 |
| anakinra Drug Profile | 71 | 2 |
| APX-3330 Drug Profile | 73 | 2 |
| BGB-324 Drug Profile | 75 | 4 |
| birabresib Drug Profile | 79 | 2 |
| CBL-0137 Drug Profile | 81 | 4 |
| CBT-1111 Drug Profile | 85 | 1 |
| CBT-3112 Drug Profile | 86 | 1 |
| ChiLob-7/4 Drug Profile | 87 | 2 |
| CYL-02 Drug Profile | 89 | 1 |
| demcizumab Drug Profile | 90 | 8 |
| durvalumab Drug Profile | 98 | 11 |
| durvalumab + tremelimumab Drug Profile | 109 | 4 |
| epacadostat Drug Profile | 113 | 4 |
| galeterone Drug Profile | 117 | 6 |
| Hu-5F9G4 Drug Profile | 123 | 2 |
| IACS-010759 Drug Profile | 125 | 1 |
| IBL-301 Drug Profile | 126 | 1 |
| IMM-101 Drug Profile | 127 | 2 |
| INCB-50465 Drug Profile | 129 | 1 |
| INO-1400 Drug Profile | 130 | 1 |
| ipafricept Drug Profile | 131 | 4 |
| itacitinib adipate Drug Profile | 135 | 3 |
| JX-929 Drug Profile | 138 | 1 |
| LY-3214996 Drug Profile | 139 | 1 |
| MCS-110 Drug Profile | 140 | 1 |
| MK-0752 Drug Profile | 141 | 1 |
| momelotinib dihydrochloride Drug Profile | 142 | 5 |
| MRK-003 Drug Profile | 147 | 1 |
| MT-477 Drug Profile | 148 | 1 |
| nivolumab Drug Profile | 149 | 30 |
| NMSP-715 Drug Profile | 179 | 1 |
| Oligonucleotide to Inhibit IDO1 for Pancreatic Ductal Adenocarcinoma Drug Profile | 180 | 1 |
| oregovomab Drug Profile | 181 | 2 |
| paclitaxel albumin bound Drug Profile | 183 | 8 |
| pamrevlumab Drug Profile | 191 | 6 |
| Parvoryx Drug Profile | 197 | 2 |
| PEGPH-20 Drug Profile | 199 | 7 |
| PF-04136309 Drug Profile | 206 | 2 |
| porfimer sodium Drug Profile | 208 | 2 |
| PSL-001 Drug Profile | 210 | 1 |
| RG-7787 Drug Profile | 211 | 1 |
| rucaparib camsylate Drug Profile | 212 | 7 |
| sacituzumab Drug Profile | 219 | 8 |
| SBP-101 Drug Profile | 227 | 2 |
| siG-12D-LODER Drug Profile | 229 | 2 |
| Small Molecule for Pancreatic Ductal Adenocarcinoma Drug Profile | 231 | 1 |
| Small Molecule to Inhibit Wnt Signal and eIF5A for Pancreatic Cancer Drug Profile | 232 | 1 |
| Small Molecules to Modulate GLT-1 for Pancreatic Ductal Adenocarcinoma Drug Profile | 233 | 1 |
| SORC-13 Drug Profile | 234 | 2 |
| vantictumab Drug Profile | 236 | 4 |
| Pancreatic Ductal Adenocarcinoma Dormant Projects | 240 | 1 |
| Pancreatic Ductal Adenocarcinoma Discontinued Products | 241 | 1 |
| Pancreatic Ductal Adenocarcinoma Product Development Milestones | 242 | 7 |
| Featured News &Press Releases | 242 | 1 |
| Jun 17, 2016: Apex Therapeutics Files IND to Initiate Phase 1 Study to Evaluate the Tolerability and Anti-Tumor Effects of APX3330 | 242 | 1 |
| May 12, 2016: ApeX Therapeutics and Researchers at Indiana University to Present Phase 1 Clinical Plan for APX3330 and Novel Approach to Addressing Therapeutic Resistance at AACR Pancreatic Cancer Meeting | 242 | 2 |
| Apr 12, 2016: Soricimed Announces Presentations at the Upcoming American Association of Cancer Research Annual Meeting | 244 | 1 |
| Jan 27, 2016: FibroGen Announces Early Phase 2 Data From a Clinical Study of FG-3019 in Combination With Chemotherapy as Neoadjuvant in Locally Advanced, Unresectable Pancreatic Cancer | 245 | 1 |
| Nov 09, 2015: Compelling Preclinical Data on Sun BioPharma's SBP-101 Presented at the 2015 American Pancreatic Association (APA) Annual Meeting | 246 | 1 |
| Oct 20, 2015: Sun BioPharma to Present Three Abstracts at the 2015 American Pancreatic Association Annual Meeting | 247 | 1 |
| Jun 25, 2013: Cleveland BioLabs And Incuron Announce Poster Presentation At ESMO 15th World Congress On Gastrointestinal Cancer | 248 | 1 |
| Appendix | 249 | 2 |
| Methodology | 249 | 1 |
| Coverage | 249 | 1 |
| Secondary Research | 249 | 1 |
| Primary Research | 249 | 1 |
| Expert Panel Validation | 249 | 1 |
| Contact Us | 249 | 1 |
| Disclaimer | 250 | 1 |